Aging Microglia is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Aging microglia, often termed "senescent" or "primed" microglia, represent the cumulative effects of cellular aging on the brain's resident immune cells. With age, microglia undergo profound phenotypic changes including telomere shortening, mitochondrial dysfunction, DNA damage accumulation, and a shift toward a pro-inflammatory "inflammaging" phenotype (Streit et al., 2004; Lowe et al., 2019). These age-related changes profoundly impact brain function and are considered a major risk factor for neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). Understanding aging microglia is essential for developing interventions that preserve microglial function during normal aging and prevent age-related neurodegeneration.
Aging microglia exhibit characteristic morphological alterations including:
Transcriptomic analyses reveal that aging microglia downregulate homeostatic genes (P2ry12, Cx3cr1, Tmem119) while upregulating:
Inflammaging refers to the chronic, low-grade inflammation that develops with age in the absence of acute infection (Franceschi et al., 2018). Microglia are major contributors to inflammaging through:
Aged microglia become "primed" - hyper-responsive to secondary immune challenges. This priming manifests as exaggerated cytokine responses to peripheral infections, surgery, or minor stressors, leading to acute delirium and accelerated cognitive decline in older adults—a phenomenon termed "microglial priming" (Perry & Holmes, 2014).
Aging microglia lose their ability to effectively clear amyloid-beta plaques, contributing to plaque accumulation in AD. Age-related changes in TREM2 signaling and lysosomal function impair microglial phagocytosis (Hansen et al., 2018). Additionally, aging microglia may accelerate tau pathology through secretion of exosomes containing phosphorylated tau seeds.
Microglial aging correlates with cognitive decline in both normal aging and AD. Interventions that rejuvenate microglial function, including CSF1R antagonists, senolytic drugs, and anti-inflammatory strategies, show promise for preserving cognitive function in aged individuals.
In PD, aging microglia adopt a pro-inflammatory phenotype that contributes to dopaminergic neuron vulnerability. Age-related mitochondrial dysfunction in microglia leads to increased reactive oxygen species production, promoting oxidative stress in the substantia nigra (Kanaan et al., 2008). The combination of aging microglia and alpha-synuclein pathology creates a feedforward loop of neurodegeneration.
Senolytic agents that selectively eliminate senescent microglia (e.g., dasatinib + quercetin, navitoclax) reduce neuroinflammation and improve cognitive function in aged animals (Zhang et al., 2019).
Colony-stimulating factor 1 receptor (CSF1R) antagonists deplete aged microglia and allow repopulation with younger, healthier cells, improving memory function in aged mice (Elmore et al., 2014).
Targeting NLRP3 inflammasome, IL-1β, or TNF-α signaling reduces microglial inflammation and may slow neurodegeneration.
The study of Aging Microglia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.